Analysis of the efficacy and safety of toripalimab in the comprehensive treatment of bladder tumors

Su Lin; Xu Qiao; Wan Shihao; Zhang Hongyu; Chen Yujie; He Yunfeng

doi:10.13406/j.cnki.cyxb.003528

您当前的位置：

首页 >

文章列表页 >

Analysis of the efficacy and safety of toripalimab in the comprehensive treatment of bladder tumors

Urinary system tumors | 更新时间：2025-10-22

- Analysis of the efficacy and safety of toripalimab in the comprehensive treatment of bladder tumors
- Journal of Chongqing Medical University Vol. 49, Issue 6, Pages: 740-744(2024)
- 作者机构：
  
  重庆医科大学附属第一医院泌尿外科，重庆 400016
- 作者简介：
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.003528
  CLC： R730.5
- Received：09 March 2024，
  
  Revised：2024-05-01，
  
  Accepted：13 May 2024，
  
  Published：28 June 2024
- 稿件说明：
移动端阅览
粟麟,许巧,万士豪,等.特瑞普利单抗在膀胱肿瘤综合治疗中的疗效和安全性分析[J].重庆医科大学学报,2024,49(6):740-744.

Su Lin,Xu Qiao,Wan Shihao,et al.Analysis of the efficacy and safety of toripalimab in the comprehensive treatment of bladder tumors[J].Journal of Chongqing Medical University,2024,49(6):740-744.
粟麟,许巧,万士豪,等.特瑞普利单抗在膀胱肿瘤综合治疗中的疗效和安全性分析[J].重庆医科大学学报,2024,49(6):740-744. DOI： 10.13406/j.cnki.cyxb.003528.

Su Lin,Xu Qiao,Wan Shihao,et al.Analysis of the efficacy and safety of toripalimab in the comprehensive treatment of bladder tumors[J].Journal of Chongqing Medical University,2024,49(6):740-744. DOI： 10.13406/j.cnki.cyxb.003528.

摘要

目的

评价真实世界中特瑞普利单抗在膀胱尿路上皮癌（bladder urothelial carcinoma，UBC）及特殊类型膀胱肿瘤（atypical bladder tumor，ABT）综合治疗中的疗效及相关安全性。

方法

纳入46例手术+特瑞普利单抗综合治疗的膀胱肿瘤患者（32例尿路上皮癌、14例特殊类型肿瘤）的资料，统计分析治疗期间出现的治疗相关不良反应发生率及疗效评估。

结果

分组：尿路上皮癌患者32例，特殊类型膀胱肿瘤14例，在使用特瑞普利单抗的综合治疗中患者整体复发率为15.2%，46例患者常见不良反应包括皮肤瘙痒（17.4%），甲状腺功能异常（15.2%），食欲下降（10.9%）等，其中3～4级不良反应发生有14例，占总不良反应的36.8%。

结论

特瑞普利单抗在UBC和ABT的综合治疗中的疗效显著，整体安全可控，但应警惕不良反应。

Abstract

Objective

To evaluate the efficacy and safety of toripalimab in the comprehensive treatment of bladder urothelial carcinoma（UBC） and atypical bladder tumor（ABT） in real-world settings.

Methods

Data from 46 patients with bladder tumors（32 with UBC and 14 with ABT） who underwent surgery combined with toripalimab treatment were included for analysis of occurrence rates of treatment-related adverse reactions and efficacy during the treatment period.

Results

For the 32 patients with UBC and 14 patients with ABT，the overall recurrence rate was 15.2% after the comprehensive treatment with toripalimab. Common adverse reactions observed in the 46 patients included pruritus（17.4%），thyroid dysfunction（15.2%），and decreased appetite（10.9%）. There were 14 events of grade 3-4 adverse reactions，accounting for 36.8% of the total adverse events.

Conclusion

Toripalimab demonstrates significant efficacy and overall manageable safety in the comprehensive treatment of UBC and ABT. However，vigilance is necessary for adverse reactions.

关键词

Keywords

references

Bilim V ， Kuroki H ， Shirono Y ， et al . Advanced bladder cancer：changing the treatment landscape [J ] . J Pers Med ， 2022 ， 12 （ 10 ）： 1745 ．

Liu YC ， Zhao YC ， Lu YJ ， et al . The role of smoking in explaining racial/ethnic disparities in bladder cancer incidence in the United States [J ] . Urol Oncol ， 2023 ， 41 （ 9 ）： 389. e1 - 389389 . e6．

Robertson AG ， Groeneveld CS ， Jordan B ， et al . Identification of differential tumor subtypes of T1 bladder cancer [J ] . Eur Urol ， 2020 ， 78 （ 4 ）： 533 - 537 ．

Kaseb H ， Aeddula NR . Bladder Cancer . StatPearls. Treasure Island (FL) ineligible companies. Disclosure : Narothama Aeddula declares no relevant financial relationships with ineligible companies . 2024 .

Rödel C ， Weiss C ， Sauer R . Trimodality treatment and selective organ preservation for bladder cancer [J ] . J Clin Oncol ， 2006 ， 24 （ 35 ）： 5536 - 5544 ．

Seidl C . Targets for therapy of bladder cancer [J ] . Semin Nucl Med ， 2020 ， 50 （ 2 ）： 162 - 170 ．

Sheng XN ， Chen HG ， Hu B ， et al . Safety，efficacy，and biomarker analysis of toripalimab in patients with previously treated advanced urothelial carcinoma：results from a multicenter phase II trial POLARIS-03 [J ] . Clin Cancer Res ， 2022 ， 28 （ 3 ）： 489 - 497 ．

Webber C ， Gospodarowicz M ， Sobin LH ， et al . Improving the TNM classification：findings from a 10-year continuous literature review [J ] . Int J Cancer ， 2014 ， 135 （ 2 ）： 371 - 378 ．

Han BM ， Liang SJ ， Jing YF ， et al . Organ preservation for muscle-invasive bladder cancer by preoperative intra-arterial chemotherapy and transurethral resection [J ] . Med Oncol ， 2014 ， 31 （ 4 ）： 912 ．

Witjes JA ， Compérat E ， Cowan NC ， et al . EAU guidelines on muscle-invasive and metastatic bladder cancer：summary of the 2013 guidelines [J ] . Eur Urol ， 2014 ， 65 （ 4 ）： 778 - 792 ．

Rahman ZA ， Hidayatullah F ， Lim J ， et al . A systematic review and meta-analysis of intraarterial chemotherapy for non muscle invasive bladder cancer：promising alternative therapy in high tuberculosis burden countries [J ] . Arch Ital Urol Androl ， 2024 ， 96 （ 1 ）： 12154 ．

Gontero P ， Sylvester R ， Pisano F ， et al . Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin：results of a retrospective multicenter study of 2451 patients [J ] . Eur Urol ， 2015 ， 67 （ 1 ）： 74 - 82 ．

Solsona E ， Iborra I ， Collado A ， et al . Feasibility of radical transurethral resection as monotherapy for selected patients with muscle invasive bladder cancer [J ] . J Urol ， 2010 ， 184 （ 2 ）： 475 - 480 ．

Wen F ， Lin TH ， Zhang P ， et al . Bladder sparing by short-course radiotherapy combined with toripalimab in high-risk/extremely high-risk non-muscle invasive bladder cancer （HOPE-04）：study protocol for a single-arm，prospective，phase II trial [J ] . BMJ Open ， 2024 ， 14 （ 1 ）： e076663 ．

Zang JY ， Zhang RY ， Jin D ， et al . Integrated longitudinal circulating tumor DNA profiling predicts immunotherapy response of metastatic urothelial carcinoma in the POLARIS-03 trial [J ] . J Pathol ， 2023 ， 261 （ 2 ）： 198 - 209 ．

Xin ZD ， You LT ， Na FF ， et al . Immunogenetic variations predict immune-related adverse events for PD-1/PD-L1 inhibitors [J ] . Eur J Cancer ， 2023 ， 184 ： 124 - 136 ．

Zhang YC ， Zhu TC ， Nie RC ， et al . Association between early immune-related adverse events and survival in patients treated with PD-1/PD-L1 inhibitors [J ] . J Clin Med ， 2023 ， 12 （ 3 ）： 736 ．

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Analysis of the safety of dinutuximab β for the treatment of neuroblastoma

Study on analgesic effect of rofecoxib on patients with advanced carcinoma

Clinical efficacy observation of multi-line therapy of inetetamab combined with pyrotinib (China double target) in patients with Her2 positive breast cancer

Related Author

Gao Yijin

Li Zhiling

Li Haonan

Yang Qiushi

Zhao Jie

Zhang An’an

Yu Liting

Han Yali

Related Institution

Department of Pharmacy，Shanghai Children’s Medical Center，Shanghai Jiao Tong University School of Medicine

Department of Hematology and Oncology，Shanghai Children’s Medical Center，Shanghai Jiao Tong University School of Medicine

Department of Pharmacy，Hainan Hospital，Shanghai Children’s Medical Center，Shanghai Jiao Tong University School of Medicine

Department of Hospice,College of Clinical Medicine,Chongqing Medical University

重庆医科大学临床学院疗养院

⁰